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Dynamic changes in DNA methylation
in ischemic tolerance
Robert Meller 1*, Andrea Pearson1 and Roger P. Simon1,2
1 Translational Stroke Program, Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA, USA, 2 Grady Memorial
Hospital, Atlanta, GA, USA
Epigenetic mediators of gene expression are hypothesized to regulate transcriptomic
responses to preconditioning ischemia and ischemic tolerance. Here, we utilized amethyl-
DNA enrichment protocol and sequencing (ChIP-seq) to identify patterns of DNA methy-
lation in an established model of ischemic tolerance in neuronal cultures (oxygen and
glucose deprivation: OGD). We observed an overall decrease in global DNA methylation
at 4 h following preconditioning ischemia (30min OGD), harmful ischemia (120min OGD),
and in ischemic tolerant neuronal cultures (30min OGD, 24 h recovery, 120min OGD).
We detected a smaller cohort of hypermethylated regions following ischemic conditions,
which were further analyzed revealing differential chromosomal localization of methylation,
and a differential concentration of methylation on genomic regions. Together, these data
show that the temporal profiles of DNA methylation with respect to chromatin hyper-
and hypo-methylation following various ischemic conditions are highly dynamic, and may
reveal novel targets for neuroprotection.
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Introduction
Pharmacological agents for neuroprotection have been disappointing in clinical trials. An under-
standing of the basic mechanisms of endogenous neuroprotection in brain, those induced by
preconditioning ischemia and resulting in a tolerant phenotype, may yield novel approaches to
reduce brain injury following ischemia (1, 2). We have previously described broad-based transcrip-
tional suppression as operative in ischemic tolerance (3), and have discovered protein effectors
of tolerance: upregulation of gene silencing polycomb proteins in tolerant brain (4). Polycomb
protein’s mechanism of action is via epigenetic chromatin binding, highlighting a putative biologic
mechanism with neuroprotective potential. DNA methylation has been prominently featured as an
epigenetic modulator in brain development as well as in brain injury (5, 6).
It has been proposed that a reduction in DNA methylation will confer protection against brain
ischemia. Global DNAmethylation increases in the brain following harmful focal ischemia, as mea-
sured by [3H]-methyl incorporation into DNA (7), but does not change the expression of DNMT1
or 3 (DNA methyltransferase, DNMT). However, the chromatin sequences that are methylated by
ischemia were not identified by Endres (7). Blocking the enzyme responsible for DNAmethylation,
DNMT, using 50 azacytidine inhibits ischemic cell death (7). Heterozygous, but not homozygous
knockouts of DNAmethyltransferase1 also show a reduction in brain infarction following modeled
ischemia (8). Therefore, reducing DNAmethylationmay protect the brain from subsequent harmful
ischemia.
An increase in DNA methylation following ischemia would be consistent with a recent study
which showed that MECP2 (methyl CpG binding protein 2), a transcription repressor, is increased
following brief ischemia (9). In addition, the DNAmethylating agentmethylazoxymethanol (MAM)
blocks ischemic tolerance induced neuroprotection (10). In that study, while the effect was attributed
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to a blockade in progenitor cell proliferation, the ability of MAM
to hypermethylate DNA such that preconditioning-induced
changes in DNA methylation are blocked, cannot be ruled out.
While it is unclear which genes are methylated in response to
ischemia, ischemia can affect DNA methyltransferase activity in
brain, and a reduction in DNA methylation may play a role in
mediating the protective effects of ischemic tolerance.
The role of DNA methylation was recently studied in an anal-
ogous model of ischemic tolerance that of tolerance to seizure-
induced brain injury (11). Following preconditioning seizures,
brain injury following status epilepticus induced by an intra-
amygdaloidal injection of kainic acid is reduced, specifically in the
CA3 subfield of the hippocampus (12–14). Similar to ischemic
tolerance, a reduction in gene expression has been reported in
seizure tolerant brain, suggesting gene repression mediates toler-
ance to both seizure and ischemic brain injury (13). In the seizure
tolerance study, DNA methylation patterns were profiled at 8 h
post seizure, and revealed a dynamic pattern whereby both an
increase and decrease in methylation were observed (11).
Thus, the role of DNAmethylation in ischemic tolerance is not
clear. Here, we offer an in-depth analysis of DNAmethylation in a
cell culture model of ischemic preconditioning-induced ischemic
tolerance (15).
Materials and Methods
Cell Culture and Ischemic Tolerance Modeling
All animal use was approved by the Morehouse School of
Medicine Institutional Animal Care and Use Committee. Primary
neuronal cultures were prepared for mixed sex litters of rats (1 day
post birth). Animals were euthanized with isoflurane, and cor-
tices dissected in an ice cold buffer (dissociation media). Tissue
was incubated with papain (37°C: 10min) and triturated. Cells
were seeded out a 5 million cells/6 cm dish. Cells were grown
in a mixture of B27 (3.5%) and Neurocult (1.5%) supplemented
NeuroBasal A media. Cells were used at 14 days in vitro (DIV).
An in vitro equivalent of ischemic tolerance is used, whereby
primary neuronal cultures are subjected to oxygen and glucose
deprivation (OGD) modeled ischemia (16–18). Cells are washed
with phosphate buffered saline, supplemented with Mg Cl2 and
Ca Cl2, and then incubated for 30 or 120min in a Thermofisher
anaerobic chamber. Cells were recovered in neurobasal A media.
For modeling ischemic tolerance, we precondition cells with
30min OGD, and injurious ischemia (120min) is applied 24 h
later. Cells were harvested 4 h following the final ischemic chal-
lenge.
DNA Preparation and Methylation Enrichment
Methylated DNAwas enriched from cell lysates (n= 2/condition)
using the Methylminer assay (Active Motif). DNA was extracted
from frozen cell pellets using the Genelute DNA Kit (Sigma).
DNAwas quantified and 2.0µg was sonicated in 200µl Tris EDTA
buffer (1 30% 10 s, 2 20% 10 s, 4°C). Sheared DNA (2000 ng)
was used as starting material for the pull down reaction according
to manufacturer’s protocol. Following pull down, the DNA was
size selected on a 1% agarose gel [200–500 base pair (bp) frag-
ments] and extracted using a PCR (polymerase chain reaction)
clean-up kit (Qiagen).
DNA Library Preparation
Samples were end-polished and ligated to barcode adapters using
T4 Kinase. Libraries were amplified using Platinum taq for 12
cycles of PCR, size selected on a 2% agarose gel, and then sub-
jected to an additional four cycles of PCR. Libraries were visu-
alized on an agarose gel (see Figure 1A), excised, and cleaned
up to remove primers (Qiagen). Samples were then subjected to
qPCR to quantify the library against a known standard. Emulsion
PCR was used to clone the libraries onto sequencing beads. The
reaction was seeded at 1.0 pmol of equimolar library (all eight
samples at the same concentration). A WFA run determined the
final concentration of beads for deposition on the sequencing
slide to obtain approximately 700 million beads deposited on
the slide. Libraries were sequenced on an Applied Biosystems
SOLiD 4 DNA sequencer using a F35 single end read. Data were
stored as csfasta files, and uploaded to a penguin cluster running
LifescopeTM for alignment to the RN5 genome (rat), using the
RefSeq annotation guide (October 2014).
Data Analysis
Data were transferred to a Dell Dimension Desktop computer
running Partek Genomic Studio v 6.6 for analysis. Data were
analyzed using the Partek ChIP and the NGS Methylation work-
flows. Output bam files were combined according to experimental
conditions for all analysis. Data were subjected to cross strand
analysis to identify the fragment window size for genomic analysis
(Figure 1C). Data were aligned to the rn5 genome, using the con-
trol sample as the reference, and a window bin size of 200 bp. Only
fragments that show enrichment with a p< 0.001 false detection
rate (FDR) were considered significant and identified in a “peaks
file.” These data were used for subsequent analysis (available upon
request).
Results
Ischemic Stimuli Result in a Reduction in Global
DNA Methylation
Methylation profiles of ischemia treated neuronal cell cultures
were identified using methylated chromatin enrichment followed
by DNA sequencing (ChIP-seq). We analyzed four treatment
groups: sham-treated cells (Control: Cont), cells subjected to
30min OGD (Preconditioning: PC) and recovered for 4 h, cell
subjected to 120min ischemia (Injurious Ischemia: Isch), and
neurons subjected to 30min OGD and recovered 24 h prior to
harmful ischemia (Tolerance: PC+ Isch). These conditions have
been established inmultiple studies as showing ischemic tolerance
(3, 16, 18). We focused on a time point of 4 h following the last
ischemic treatment to identify dynamic changes in methylation
that may be responsible for subsequent gene expression changes.
Quantitative analysis of assembled libraries on an agarose gel
suggests a global decrease in DNAmethylation, detected using the
Methylminer assay. Interestingly, methylation was reduced fol-
lowing all ischemia treatment protocols (Figures 1A,B). Libraries
were assembled and DNA concentrations were normalized prior
to sequencing. The sequenced data were aligned to the rn5 refer-
ence genome; there were similar numbers of alignments in each
experimental group (mean of 20.2 million reads 1.8 million
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FIGURE 1 | Global decreases in DNA methylation revealed by DNA
sequencing. (A) Agarose Gel showing approximate size of prepared libraries
following enrichment of methyl-DNA using the methylminer assay. Libraries were
amplified using PCR prior to running the gel. A–d refer to two independent
experiments, A, a Cont, B, b-PC, C, c-Isch, D, d-PC+ Isch. (B) Optical
quantification of bands in (A) using Kodak Biostation 4000MM.
(C) Quantification of number of reads aligned to the Rn5 reference genome
using Lifescope software. Data are n= 2, meanSD. (D) Partek generated
Hilbert graph showing methylation across the rat genome. Chromosome
location is represented on the bottom of the figure and conditions are denoted
on the left. Higher methylation is represented by warm colors (red) and
hypomethylation by blue. (E) Expanded view of Chromosome X Hilbert Graph,
showing representative decrease in methylation across all treatments compared
to control.
reads; Figure 1C). The equivalent number of aligned reads is
due to the concentration normalization step in the sequencing
protocol. Therefore, all subsequent analysis reveals differences
of methylation enrichment patterns rather than absolute DNA
methylation levels.
In order to compare datasets, we combined the reads from
each experimental condition (Cont, PC, Isch, PC+ Isch), result-
ing in 30–40 million aligned reads per condition. Global methy-
lation status was visualized with a Hilbert graph (19). Intensity
of methylation is represented by red, and weaker intensity is
represented as blue. Similar to previous published studies, the
visualization of DNA methylation patterns showed a diffuse pat-
tern of reads across the genome (Figure 1D). However, it is of note
that the intensity of reads is lower globally across the genomes
of the PC, Ischemia, and PC+ Ischemia treated cells, consistent
with the library analysis (Figure 1A). Of note, we also observed a
lower global representation of methylation on the X chromosome
(Figure 1E).
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FIGURE 2 | Analysis of DNA methylation peaks reveals differential
chromosomal methylation. (A) Cross strand analysis to determine library
size for peak analysis. The PC and ischemia curves overlap (Cont: blue, PC:
green, Isch: red, and PC+ Isch: black). (B) Quantification of number of
peaks in each treatment condition, and the number of unique peaks in each
condition denoted by an asterisk. Data from the two sets were combined.
(C). Distribution of raw peak occurrence by chromosome for PC, Ischemia,
and PC+ Isch treated cells. The size of the chromosome is plotted on the
right axis. (D). Normalization of chromosome location data, by number of
peaks and per Mbp of chromosome to reveal selective enrichment of
chromosome patterns of DNA methylation. Note high relative methylation of
mitochondria (discontinuous axis).
Apeak analysis was performed on theDNA-seq data to identify
clusters of methylation and relative differences in methylation
compared to control. The window for the fragment size for anal-
ysis was determined by performing a cross strand analysis (20)
(Figure 2A). Samples showed an approximate peak of around
150 bp (arrow Figure 2A). Reads were analyzed using a 150 bp
fragment window, and using the control samples as a reference (to
compare DNA methylation to control). The genome was divided
into 100 bp windows, which could be combined. Data were fit to
a negative binominal model with a peak cutoff false detection rate
(FDR) of p< 0.001. From this analysis, 5035 peaks were identified
in each of the four conditions. When we plot the number of
methylation peaks (Figure 2B), we observed that the number of
peaks decreases in the PC, Ischemia, and PC+ Ischemia treated
cells. The number of peaks unique to each condition are also plot-
ted, and these have a similar distribution (peaks unique to each
condition are marked with an asterisk; Figure 2C). Interestingly,
although global methylation is reduced in ischemia-treated cells
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compared to PC-treated cells (Figure 1B), the number of hyper
methylated regions is the same (Figure 2B). Our interpretation of
this result is that global levels of DNA methylation are reduced
4 h following harmful ischemia, but individual genes may show
a strong increase in methylation, which we further investigated
(below).
Dynamic Changes in Methylation Following
Ischemia Show Chromosomal and Functional
Bias
In order to identify genes whose methylation increased following
ischemia treatments, we subjected the data to a one-tailed negative
binominal test and selected a cut off FDR value of 0.05. Compared
to the control sample, 618 regions show significant enrichment,
which we interpreted as increased methylation. There were more
enriched regions in the ischemia group (345) compared to those
treated with preconditioning only (187), or in tolerant samples
(65) (Figure 2D).
We separated the differentially methylated peaks by treatment,
and identified which genomic feature they were close to and
which chromosome they align with. Analysis of the enriched
methylation peak distribution revealed an increase in chromo-
some 2, 12, and 13 methylation in the ischemia-treated cells
(Figure 2C). In order to assess relative chromosomal distribu-
tion, we normalized the number of peaks to the total number
of peaks/condition, and then scaled to the size of the chromo-
some (Figure 2D). Global methylation was reduced following
PC+ Ischemia/tolerance (Figure 1B); it is of note that chro-
mosome 1, 7, and 17 showed relative enhancements in hyper-
methylation compared to control. Following PC, methylation of
chromosome 6, 9, 16, and 20 showed enhanced hypermethylation
compared to control. There was no chromosome selective enrich-
ment of hypermethylated regions in ischemia-treated cells; rather,
hypermethylated chromosomes were common preconditioned
cells (chromosome 2 and chrX), or preconditioned cells subjected
to harmful ischemia (chromosome 3, 12, and 13) (Figure 2D).
This suggests that different chromosomes show predominant
methylation in response to various ischemic treatments, which
may result in differential activation of gene expression/repression
in response to these stimuli.
The lists of significantly regulated genes were then analyzed,
according to which genomic feature they correspond with using
the RefSeq Transcripts Annotation guide (24 October, 2014)
(Figure 3A). Promoters were defined as 5000-0 bases downstream
of the transcription start site. Data from multiple introns and
exons (CDS) were combined into one category. The most notable
feature was the very high representation of intergenic regions in
this data set; yet, only 1% of the genome encodes genes. It is not
clear whether these intergenic associated regions of methylation
are associated with non-transcribed DNA or novel transcripts
of RNA, which are as yet unannotated (or not in the refSeq
guide). Ischemia-treated and tolerant cells appear to have similar
concordance with a control (total) distribution of methylation
across genomic features. In contrast, following preconditioning
ischemia, there was a relative increase in PC-mediated exon
and intron-associated methylation, and a decrease in intergenic
methylation (Figures 3A,B).
Finally, we investigated the location of reads relative to the
transcription start site (TSS). This analysis is independent of the
gene name; so, it only considers the relative location of peaks to
the closest TSS. All samples had a similar profile in that we saw a
relatively even distribution before and after the TSS (Figure 3B).
A notable exception is at the actual TSS where the depth of reads
is higher. When we expand this region (Figure 3C), we observed
that control, PC, and ischemia treated samples showed a clustering
around the TSS; in contrast, the largest peak from the tolerant
cells was approximately 150 bp downstream of the TSS. Whether
this was due to the loss of global methylation in these samples
or a more selective methylation mark close to the TSS is not
yet clear. Similarly, samples from PC and Ischemia treated cells
also show a peak, but closer to 100 bp downstream of the TSS.
The significance of these marks on gene expression awaits further
investigation.
Pathway Analysis of Methylated Regions
For each treatment group, we created lists of genes closest to the
methylation peaks, and genes unique to each treatment group.
We performed a pathway analysis on the gene lists associated
with methylated regions. Fisher’s exact test was performed, and
pathways were restricted to have at least two genes present. From
this analysis, we first looked at enrichment scores and enrichment
p-values, with a cut off of p< 0.05. (Table 1A depicts the pathways
associated with the methylated genes in control, and 1B unique to
control). In control samples, 13/19 of the pathways were associ-
ated with immune and inflammatory responses, or were identi-
fied as having genes associated with the immune system. Unique
to control, we observe 19 pathways showing enrichment, again
showing a high number of immune system associated pathways
(Table 1B).
Following preconditioning ischemia, 17 pathways are identi-
fied, 10 of which are immune system, but 2 are associated with
serotonin (Table 2). In the unique PC gene list, two-third of
the pathways identified with synaptic pathways rather than the
immune system. Following harmful ischemia (Tables 3A,B), 15
pathways showed enrichment, of which 13 are immune function
associated. When we look at pathways unique to ischemia, three
pathways associated with the synapse and receptor ligand interac-
tions are identified. In ischemic tolerance, we do not observe any
significant pathways identified, but one pathway, insulin secre-
tion, was identified in the unique tolerance sample (Table 4). The
low number of pathways identified in the tolerant sample is due
to the low number of methylation associated peaks identified in
these samples.
Discussion
Methylation of DNA is an important mechanism by which epi-
genetic modulation of gene expression occurs. Here, we show that
both protection inducing ischemia (preconditioning) and harmful
ischemia reduce global DNA methylation. The decrease in global
methylation was more pronounced in ischemic tolerant cells.
While global methylation was reduced, we observe an increase in
methylation in chromosome 2, 12, and 13 in ischemia-treated cells
and chromosome 1, 7, and 17 in tolerant cells, suggesting selec-
tive enhancement/targeting ofmethylation at these chromosomes.
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FIGURE 3 | Genomic location of DNA methylation following ischemia
treatments. (A) Genomic locations of peaks as identified with RefSeq
annotation guide. Most DNA methylation peaks are deemed intergenic, or
between genes. Total represents a combination of all of the peaks and then
analyzed for genomic location. Enlargement of non-intergenic associating reads,
grouped by condition [N.B. re-draw of data in (A)]. (B) Analysis of reads relative
to the transcription start site (+6000 to  6000 bases). Note the uniform
distribution except at the TSS. The data are analyzed by determining the
frequency of reads in 100 bins across the range of the x axis. (C) Enlargement
of the  22 to +200 base region around the transcription start site.
While the distribution ofmethylation across ischemic and tolerant
genomic regions was similar in incidence, in the preconditioned
cells an exon associated methylation induction and attenuation
in intergenic methylation were noted. A clustering of differential
methylation at transcriptional start sites was observed in all cell
treatment groups.
Similar global changes in methylation are reported in brain
following injurious status epilepticus when compared to changes
seen after induction of seizure tolerance (11). The hypothesis in
both our ischemia studies and those of seizure was that the acti-
vation of neuroprotective mechanisms via previously described
genomic reprograming and transcriptional suppression might
occur via epigenetic processes, specifically by DNA methyla-
tion. However, in both our study of ischemia and the seizure
study, a profound global hypomethylation event was observed in
response to cell stress (ischemia or seizures). While this contrasts
with studies showing increased methylation following harm-
ful ischemia (7), it should be noted that the present tolerance
and seizure studies used shorter recovery times following the
stress 4 h (present study) and 8 h (11). It should also be noted
that 4 h following preconditioning ischemia and precondition-
ing seizures, we have noted larger changes in gene expression
compared to 24 h post preconditioning [(21) and Meller, unpub-
lished].
Global demethylation was more pronounced in the ischemic
tolerant group (cells subjected to preconditioning and harmful
ischemia) compared to the ischemia or PC only-treated cells. It
is not clear whether the reduction in methylation is due to the
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TABLE 1 | (A) List of pathways identified from closest gene to methylation peaks in control MeDNA sample; (B) list of pathways identified from closest gene
to methylation peaks unique to control MeDNA sample.








# genes in list,
in pathway
(A)
Allograft rejection kegg 17:17 3.4889E-08 11:48 0:62 7
Autoimmune thyroid disease kegg 16:61 6.1039E-08 10:61 0:62 7
Viral myocarditis kegg 15:35 2.156E-07 8:86 0:62 7
Antigen processing and presentation kegg 14:60 4.5532E-07 7:95 0:62 7
Graft-versus-host disease kegg 14:09 7.6324E-07 10:17 0:62 6
Cell adhesion molecules (CAMs) kegg 13:26 1.7457E-06 5:16 0:62 8
Type I diabetes mellitus kegg 13:23 1.7874E-06 8:82 0:62 6
Phagosome kegg 10:21 3.6978E-05 4:12 0:61 7
Epstein–Barr virus infection kegg 8:86 0.00014 3:33 0:62 7
Endocytosis kegg 8:69 0.00017 3:24 0:62 7
Herpes simplex infection kegg 7:62 0.00049 3:28 0:62 6
HTLV-I infection kegg 7:39 0.00062 2:62 0:62 7
Viral carcinogenesis kegg 7:18 0.00076 3:02 0:62 6
Natural killer cell mediated cytotoxicity kegg 4:37 0.01264 3:45 0:53 3
Linoleic acid metabolism kegg 4:22 0.01464 6:06 0:34 2
Lysine degradation kegg 3:77 0.02312 4:76 0:47 2
Serotonergic synapse kegg 3:66 0.02585 2:63 0:33 3
Hippo signaling pathway kegg 3:13 0.04357 2:14 11:40 3
Synthesis and degradation of ketone bodies kegg 3:00 0.04965 11:11 0:57 1
(B)
Allograft rejection kegg 20:47 1.29E-09 11:48 0:26 7
Autoimmune thyroid disease kegg 19:90 2.27E-09 10:61 0:26 7
Viral myocarditis kegg 18:62 8.22E-09 8:86 0:26 7
Antigen processing and presentation kegg 17:85 1.76E-08 7:95 0:26 7
Graft-versus-host disease kegg 16:84 4.84E-08 10:17 0:26 6
Type I diabetes mellitus kegg 15:98 1.15E-07 8:82 0:26 6
Cell adhesion molecules (CAMs) kegg 13:94 8.85E-07 4:52 0:26 7
Epstein–Barr virus infection kegg 11:90 6.77E-06 3:33 0:26 7
Endocytosis kegg 11:72 8.16E-06 3:24 0:26 7
Phagosome kegg 10:59 2.53E-05 3:53 0:26 6
HTLV-I infection kegg 10:33 3.26E-05 2:62 0:26 7
Herpes simplex infection kegg 10:17 3.84E-05 3:28 0:26 6
Viral carcinogenesis kegg 9:70 6.15E-05 3:02 0:26 6
Linoleic acid metabolism kegg 5:06 0.0063 6:06 0:27 2
Arachidonic acid metabolism kegg 3:55 0.0288 2:74 0:27 2
Retinol metabolism kegg 3:50 0.0302 2:67 0:27 2
Steroid hormone biosynthesis kegg 3:47 0.0310 2:63 0:27 2
Chemical carcinogenesis kegg 3:36 0.0348 2:47 0:27 2
Natural killer cell mediated cytotoxicity kegg 3:23 0.0397 2:30 0:27 2
repeated exposure of the tissue to ischemic stress, resulting in
an additive effect, or whether it is unique to the tolerance phe-
nomenon. Hypermethylation was also reduced in this group com-
pared to the other ischemia treatments. Since fewer “enriched”
hypermethylation peaks were identified in the tolerance group,
our mapping software only found one regulated pathway (insulin
secretion). A reduction in hypermethylation in ischemic tolerance
was, perhaps, unexpected given the established observations of
gene silencing in ischemic tolerance. Indeed, on first appear-
ance our data appear to contradict the hypothesized dogma that
ischemic tolerance is associated with gene silencing (3, 4). How-
ever, care should be taken in interpreting these data sets together
in this way, given that the current ischemic tolerance study identi-
fied chromatin methylation status 4 h following the final harmful
insult, whereas gene expression and protein levels were reported
24 h following the final insult (3, 4). These discrepancies clearly
support the need for further detailing the temporal profiles of both
gene expression and chromatin methylation in response to such
stimuli.
Most of the differential methylation is intergenic, which could
associate with either non-transcribed DNA regions, or currently
unannotated RNA species in the genome. RNA sequencing based
transcriptome analysis shows approximately 30% of RNA is from
such unannotated regions (22). It is interesting that there is a
reduction in methylation in these regions of PC treated cells.
When we remove the intergenic reads (Figure 3B), we observed
that following PC there is a relative increase in methylation in
coding regions compared to harmful ischemia in which methy-
lation was focused more in intergenic regions. Whether this sug-
gests changes in structural organization of chromatin or non-
coding RNAs remains to be determined. In tolerant cells, we
observed a reduction in coding region associated with methylated
peaks. This may be due to the lower number of reads in this
sample set, or a genuine decrease in exon associated methylation.
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TABLE 2 | (A) List of pathways identified from closest gene to methylation peaks in PC MeDNA sample; (B) list of pathways identified from closest gene to
methylation peaks unique to PC MeDNA sample.








# genes in list,
in pathway
(A)
Serotonergic synapse kegg 8:08 0:00031 4:39 1:13 5
Graft-versus-host disease kegg 5:60 0:003684 5:08 0:74 3
Allograft rejection kegg 5:51 0:004049 4:92 0:74 3
Autoimmune thyroid disease kegg 5:29 0:005055 4:55 0:74 3
Type I diabetes mellitus kegg 5:20 0:005496 4:41 0:74 3
Viral myocarditis kegg 4:79 0:008333 3:80 0:74 3
Antigen processing and presentation kegg 4:49 0:011193 3:41 0:74 3
Phagosome kegg 4:41 0:012174 2:35 0:71 4
HTLV-I infection kegg 4:36 0:01282 1:87 0:87 5
Linoleic acid metabolism kegg 4:33 0:013157 6:06 1:17 2
Retrograde endocannabinoid signaling kegg 4:18 0:015373 3:03 1:20 3
Herpes simplex infection kegg 4:16 0:015608 2:19 0:80 4
Tryptophan metabolism kegg 3:83 0:021766 4:65 0:98 2
Endocytosis kegg 3:62 0:026903 1:85 0:80 4
Ovarian steroidogenesis kegg 3:55 0:028851 4:00 0:81 2
Synthesis and degradation of ketone bodies kegg 3:06 0:04702 11:11 0:57 1
Cell adhesion molecules (CAMs) kegg 3:02 0:048765 1:94 0:74 3
(B)
Retrograde endocannabinoid signaling kegg 3:633 0:026 2:020 2:506 2
HTLV-I infection kegg 3:518 0:030 1:124 2:922 3
Serotonergic synapse kegg 3:372 0:034 1:754 2:126 2
Dorso–ventral axis formation kegg 2:936 0:053 4:762 5:644 1
TABLE 3 | (A) List of pathways identified from closest gene to methylation peaks in ischemia MeDNA sample; (B) List of pathways identified from closest
gene to methylation peaks unique to ischemia MeDNA sample.








# genes in list,
in pathway
(A)
Cell adhesion molecules (CAMs) kegg 6.42 0:0016 3:226 0:905 5
Serotonergic synapse kegg 5.61 0:0037 3:509 2:831 4
Graft-versus-host disease kegg 5.44 0:0043 5:085 0:785 3
Allograft rejection kegg 5.35 0:0047 4:918 0:785 3
Autoimmune thyroid disease kegg 5.13 0:0059 4:545 0:785 3
Type I diabetes mellitus kegg 5.05 0:0064 4:412 0:785 3
Viral myocarditis kegg 4.63 0:0097 3:797 0:785 3
Natural killer cell mediated cytotoxicity kegg 4.37 0:0126 3:448 1:242 3
Antigen processing and presentation kegg 4.34 0:0130 3:409 0:785 3
Linoleic acid metabolism kegg 4.22 0:0146 6:061 1:969 2
Phagosome kegg 4.22 0:0148 2:353 0:767 4
Neuroactive ligand-receptor interaction kegg 3.94 0:0194 1:786 6:661 5
Glutamatergic synapse kegg 3.80 0:0225 2:778 11:711 3
Endocytosis kegg 3.43 0:0323 1:852 0:816 4
Ribosome kegg 3.36 0:0348 2:344 3:650 3
(B)
Neuroactive ligand-receptor interaction kegg 6.94 0:000969 1:79 10:74 5
Glutamatergic synapse kegg 5.66 0:003468 2:78 11:71 3
GABAergic synapse kegg 3.68 0:025125 2:33 9:56 2
TABLE 4 | List of Pathways identified from closest gene to methylation peaks unique to tolerance MeDNA sample.








# genes in list,
in pathway
Insulin secretion kegg 4.35823 0.012801 1.19048 18.4401 1
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Additionally, methylation of intronic regions was increased fol-
lowing PC. This may be due to non-coding RNAs associated
with intronic regions, or may represent regulation of alternative
splicing of gene transcripts, which may occur following precondi-
tioning (Meller, unpublished observation) or ischemia (23).
Following ischemia treatments, we observed a chromosomal
difference in patterns of enhanced methylation compared to
control cells. This suggests that chromosomal specific patterns
of chromatin methylation may be regulated following various
ischemic stimuli. How specific chromosomes are targeted for
enhanced methylation is not clear, but studies of methylation
following seizures support differential chromosomal location of
methylation events following stress (11). Our analysis focused on
specific increases in methylation clusters, because we observed
global decreases in methylation events. Chromosomal specific
gene expression effects of excitotoxicity have been reported previ-
ously (24). Chromosomal bias may be associated with movement
of chromosomes into active nuclear territories (25). For example,
chromosome X movement has been described following epilepsy
(26). Changes in nuclear structure and epigeneticmarks have been
reported in response to synaptic and excitotoxic signaling (27).
Our study may upon first analysis appears to contradict the
study of Endres; however, it should be noted that very different
methodologies were utilized in these studies. In the Endres study,
the incorporation of radiolabeled methyl groups into genomic
DNAwasmeasured. As such increasedmethylationmay be due to
dynamic DNA methylation or DNA methylation following DNA
damage and repair, which has been reported following ischemia
(28, 29).We also observed a global decrease inmethylation follow-
ing harmful ischemia, and DNA damage would be expected fol-
lowing harmful ischemia, hence re-methylation may occur. DNA
methylation blockers are neuroprotective against ischemia (7).
The agents were administered 10min prior to harmful ischemia.
However, the temporal profile of protection afforded by such
blockade is not clear. In our study, we observed a reduction
in global DNA methylation in tolerant neurons, suggesting that
preventing the increased specific methylation observed following
harmful ischemia could be protective.
In contrast, our study correlates with the observations of
Miller-Delaney that DNA hypomethylation is associated with
neuroprotection. In the current study, a methyl DNA binding
protein related to the methyl binding domain of MeCP2 was used
to enrich chromatin, in contrast to an anti-Me-cytosine antibody
enrichment procedure (11). Increased MeCP2 has been reported
in brain 24 h following preconditioning ischemia due to the loss in
the levels of miR-132 (9). Thus, some of the differences in individ-
ual gene/chromatin region identification may be due to methods
of enrichment. We also utilized DNA sequencing of the whole rat
genome vs. mouse promoter arrays (11), which may also reveal
differences between studies. Furthermore, sequencing libraries
were normalized to approximate equimolar concentrations, prior
to seeding the cloning PCR. The effect of this is to ensure even rep-
resentation of the libraries in the sequencing reactions. However,
as a result, some of the global decreases in methylation become
less apparent. This was in part controlled for by comparing the
methylation to the control sample, thereby revealing the dynamic
changes in methylation. Clearly, more analysis of such studies will
reveal additional information, especially when more advanced
analysis methodologies and tools become available to incorporate
such aspects of sequencing.
In summary, we performed a DNA methylation study using
next generation sequencing which revealed dynamic changes in
DNA methylation following preconditioning ischemia and in
ischemic tolerance. Our study showed that 4 h following pre-
conditioning ischemia, harmful ischemia, and in tolerant cells,
DNA hypomethylation predominates as the response. However,
selective and significant increases in hypermethylation events can
also be observed, especially in response to harmful ischemia. The
consequence of these events upon transcription awaits definition,
but this study suggests that the temporal profile of epigenetic reg-
ulation of gene expression events needs further study to improve
our understanding of this critical transcription control mecha-
nism, and the identification of novel targets for neuroprotection
from stroke induced brain injury.
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